All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-PD-L1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human PD-L1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-PD-L1 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of NSCLC, Melanoma, Breast Cancer, Glioma, Lymphoma, Leukemia and Various Urinary Tract Tumors, Gastrointestinal Tumors, Reproductive System Tumors.
CAR Construction : Atezolizumab scFv-BBζ Fig.1 Expansion of PD-L1-CAR and CD19-CAR T cells in vitro for 14 days. Data represented technical triplicates using T cells from one donor and were displayed as mean ± SEM. Liu, M., Wang, X., Li, W., Yu, X., Flores-Villanueva, P., Xu-Monette, Z. Y., ... & Li, Y. (2020). Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis, 9(8), 1-11. |
CAR Construction : Atezolizumab scFv-BBζ Fig.2 Cytotoxic activity of PD-L1-CAR T cells after 4 and 20 h of co-culture with human NSCLC cell lines. PD-L1-CAR T cells and CD19-CAR T cells were used as effector cells at various ratios of effector (E): target (T). Liu, M., Wang, X., Li, W., Yu, X., Flores-Villanueva, P., Xu-Monette, Z. Y., ... & Li, Y. (2020). Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis, 9(8), 1-11. |
CAR Construction : Atezolizumab scFv-BBζ Fig.3 Flow cytometry histogram of the surface antigen expression of PD-L1 in human NSCLC cell line. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. Liu, M., Wang, X., Li, W., Yu, X., Flores-Villanueva, P., Xu-Monette, Z. Y., ... & Li, Y. (2020). Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis, 9(8), 1-11. |
CAR Construction : Atezolizumab scFv-BBζ Fig.4 Serial bioluminescence imaging of tumor progression and regression in each group (n = 3 mice per group). Experimental design of tumor cell xenograft model treated with CAR T cells and/or irradiation. Liu, M., Wang, X., Li, W., Yu, X., Flores-Villanueva, P., Xu-Monette, Z. Y., ... & Li, Y. (2020). Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis, 9(8), 1-11. |
CAR Construction : Atezolizumab scFv-BBζ Fig.5 Representative images of CD3 IHC in PD-L1-CAR T cell-treated and irradiation-treated NSCLC tumors. Scale bars, 100 µm. Liu, M., Wang, X., Li, W., Yu, X., Flores-Villanueva, P., Xu-Monette, Z. Y., ... & Li, Y. (2020). Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis, 9(8), 1-11. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-PD-L1 (Atezolizumab) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP1381). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION